When a plan will not approve Zepbound, four routes remain. The manufacturer sells the drug directly to self-paying patients. Supervised practices dispense compounded tirzepatide. Older weight-management drugs the plan already pays for are still available. And a second approved indication sometimes changes the coverage question entirely. Fit depends less on monthly price than on expected duration.
Price the year, not the month
Treatment with an incretin drug is not a one-month purchase, and the evidence on stopping is consistent. The STEP 1 trial extension followed participants after semaglutide was withdrawn and found most of the lost weight returned over the following year. SURMOUNT-4 ran the same question from the other direction, taking people who had already lost weight on tirzepatide and randomizing them to continue or switch to placebo. The continuation group held their result. The placebo group did not.
That reshapes the arithmetic of a self-pay decision. A route that is affordable for two months and impossible for twelve is not cheap, it is a postponed version of the same problem. The useful first step is to name a monthly number the household could carry for a year without strain, then look only at routes that clear it. Anything above that line is a bridge, and bridges should be chosen knowing they end.
Ask the second-indication question before pricing anything
Tirzepatide reaches pharmacies under two brand names for different purposes. Zepbound holds approvals for chronic weight management and, separately, for moderate to severe obstructive sleep apnea in adults with obesity, an indication supported by the SURMOUNT-OSA trial program. Mounjaro is the same molecule approved for type 2 diabetes. The prescribing information for each brand is public through DailyMed.
This matters because benefit exclusions tend to be written by category rather than by molecule. Medicare is the clearest example: Part D carries a statutory exclusion for agents used for weight loss, which is why coverage conversations for older adults so often turn on whether a separate approved indication is documented rather than on obesity itself. Commercial plan documents vary enormously and no general rule can be stated about them, but the same structural logic shows up often enough that reading the actual exclusion language is worth twenty minutes.
None of this is something a patient can manufacture. Either a second condition is present and documented or it is not. Untreated sleep apnea is common in this population and evaluation for it is an ordinary clinical step, not a coverage maneuver, but the finding has to be real.
The manufacturer self-pay channel
Eli Lilly sells Zepbound in single-dose vials to self-paying patients through its own channel, outside the pharmacy benefit. The advantage is straightforward: it is the FDA-approved product with a known potency and the standard label. The published self-pay price has changed more than once since launch and differs by dose, so any figure quoted secondhand belongs in the category of things to verify at the source before building a budget on it.
The separate copay savings card is a different program from self-pay pricing and generally applies to people who already hold commercial coverage, which is the exact group that has not been denied. Reading the two programs as interchangeable is a common and expensive mistake.
The direct-pay market has grown crowded, and comparing published prices across it is now its own small task. LillyDirect routes the manufacturer’s own vials, while telehealth companies such as Ro, Hims and Hers, and Henry Meds list self-pay figures of their own, and HealthRX publishes its Zepbound self-pay pricing online as well. What each headline number includes differs enough that reading them side by side matters, since a figure that leaves out the visit or shipping is not the amount a household ends up paying.
Supervised compounded programs
Telehealth practices working with compounding pharmacies dispense tirzepatide and semaglutide preparations at flat monthly rates. The central fact about this route is that compounded drugs are not FDA-approved. The agency does not review them for safety, effectiveness or manufacturing quality, and its compounding guidance limits when a pharmacy may prepare what amounts to a copy of a commercially available approved drug. A pharmacovigilance analysis of adverse event reports involving compounded GLP-1 products found dosing error patterns tied to concentration differences between preparations, which is a practical risk rather than a theoretical one.
Pricing here is usually a single monthly figure covering the consultation, the medication and shipping, which is easier to plan around than a pharmacy price that moves with deductible status. Supervised practices such as FormBlends publish that figure before intake, and the tradeoff for the price transparency is a product that has not been through FDA review.
What the routes actually differ on
| Route | Product status | What drives the price | Best suited to |
|---|---|---|---|
| Manufacturer self-pay vials | FDA-approved | Dose and manufacturer pricing decisions | People who want the approved product and can hold the cost |
| Supervised compounded program | Not FDA-approved | Flat practice pricing, dose tier | People needing a predictable monthly number |
| Older covered drug | FDA-approved | Plan copay tier | People whose plan blocks incretins but not everything |
| Second-indication route | FDA-approved | Plan cost share once approved | People with a documented qualifying condition |
Drugs the plan already pays for
Weight management existed before incretins, and the older agents did not stop working when the new ones arrived. Phentermine, phentermine with topiramate, naltrexone with bupropion, orlistat and liraglutide all remain available, and plans that exclude the newest drugs frequently still cover some of them. Clinical guidance from gastroenterology and from the 2025 pharmacotherapy update places these agents lower on average effect than tirzepatide, and that gap is real. It is also a comparison across separate trials with different populations, not a head-to-head result, so the honest framing is that the older drugs do less on average while still doing something for a meaningful share of people.
For someone whose alternative is nothing at all, a covered drug at a normal copay beats an uncovered drug at a price that ends treatment in March.
Questions readers ask
Does a denial for Zepbound also block Mounjaro?
Not necessarily, because the two brands carry different approved indications and plans commonly treat them as separate entries on a drug list. Mounjaro is approved for type 2 diabetes, so it is only relevant where that diagnosis exists. Substituting brands to work around an exclusion is not something a prescriber can do without the underlying condition.
Is compounded tirzepatide the same drug at a lower price?
It contains the same active ingredient but it is not the same product. Compounded preparations are made outside the approval pathway, without FDA review of manufacturing quality, potency or labeling, and concentrations differ between pharmacies. That difference is the reason dosing errors have appeared in adverse event reporting, and it is worth understanding before comparing on price alone.
Can a health savings account be used for self-pay doses?
Prescribed medication is generally an eligible expense under these accounts, which lowers the effective cost by the tax rate rather than the sticker. It does not change availability or approval status. Account rules and contribution limits are set federally and administered by the plan, so the details are worth confirming with the account administrator.
How long does it take to regain weight after stopping?
Published follow-up suggests it is gradual rather than immediate, with a substantial share of lost weight returning over roughly a year in the semaglutide withdrawal extension. Maintenance data with tirzepatide points the same way. The practical implication is that a short affordable course delivers a temporary result unless something replaces it.
